Stock analysis, AI verdict, fundamentals & technical signals
Rating: BUY
Price: $6.84 Analyst target: $26.33 Upside: 284.94%
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company is headquartered in Lexington, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.